The Lancet publishes detailed vosoritide phase III data demonstrating statistically significant increase in annualized growth velocity (AGV) over 52 weeks in children with achondroplasia.- BioMarin
BioMarin Pharmaceutical Inc. announced that The Lancet has published online results from a randomized, double-blind, phase III, placebo-controlled, multicenter trial for vosoritide , an investigational analog of C-type Natriuretic Peptide (CNP), in children aged 5 to 18 years with achondroplasia.